Tag: Humacyte
Humacyte publish six-year outcomes in study of HAV for peripheral arterial...
Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced...
Human-tissue engineered blood vessels remain durable at six years in PAD...
Mid-term results from a phase II study of surgical bypass using the Human Acellular Vessel (HAV; Humacyte) demonstrated an overall secondary patency rate at...
Ukrainian surgeons present clinical update on Human Acellular Vessel in vascular...
Humacyte recently announced the presentation of a clinical update on the Human Acellular Vessel (HAV) for the treatment of vascular trauma. The update was...
Humacyte provides update on patients treated at front-line hospitals in Ukraine...
Humacyte today announced that the first Ukrainian patients have received implants of the Human Acellular Vessel (HAV) for the treatment of vascular trauma injuries....
Humacyte’s Human Acellular Vessel for limb salvage evaluated in multiple complex...
Humacyte today announced results from the first series of compassionate use cases of the company’s investigational Human Acellular Vessel (HAV) for the treatment of...
Humacyte to present long-term follow-up data from Phase 2 vascular access...
Humacyte has announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in haemodialysis...
Humacyte commences phase II vascular trauma trial
Humacyte has announced the initiation of a US phase II vascular trauma clinical trial of Humacyl, its investigational human acellular vessel, for vascular replacement...
Humacyte appoints Doug Blankenship as chief financial officer
Humacyte has announced the appointment of Douglas L Blankenship as chief financial officer, effective Monday, 8 October, 2018.
According to a company release, Blankenship is...
Humacyte appoints Jeffrey Lawson as president and CEO
Humacyte, an innovator in biotechnology and regenerative medicine, has announced that Jeffrey Lawson has been appointed president and chief executive officer. The former chairman...
Fresenius and Humacyte enter strategic global partnership with US$150M equity investment
Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, have announced...
Humacyte’s Humacyl receives US FDA expedited review designation
The US Food and Drug Administration (FDA) has granted Humacyte’s Humacyl investigational human acellular vessel (HAV) Regenerative Medicine Advanced Therapy (RMAT) designation.
This designation means...
Humacyte commences US phase II arterial bypass clinical trial
Humacyte has announced the initiation of a US phase II arterial bypass clinical trial of Humacyl, an investigational human acellular vessel, to test its safety...
